New hope for rare autoimmune disease: baricitinib trial underway
NCT ID NCT05300932
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 4 trial tests whether baricitinib, a drug already used for rheumatoid arthritis, can help people with systemic sclerosis—a rare disease that causes skin thickening and organ damage. Sixty participants will receive either baricitinib or standard treatment for 24 weeks, then all will take baricitinib for another 24 weeks. The main goal is to see if baricitinib reduces skin thickness better than current therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Baricitinib (Olumiant)
What this could lead to
If it works, baricitinib could offer a new treatment option to control skin fibrosis and other symptoms in systemic sclerosis.
What could go wrong
This is a small, early-phase trial with only 60 participants. Baricitinib may not prove more effective than standard care, and side effects like infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of RheumatologyTongji Hospital
Wuhan, Hubei, 430030, China
-
Tongji Hospital
Wuhan, Hubei, 430030, China